Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Ripretinib

ddcd5fd1-5410-5cb1-8a89-6ac687cab9ae · FDA Approved · targets C_KIT, PDGFRA, PDGFRB

Ripretinib

MeasuredReference

Ripretinib targets ARAF, BRAF, RAF1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ARAFBRAFRAF1C_KITYSK4_MAP3K19

Top hallmarks

  • tumor promoting inflammation5.4k
  • evading apoptosis3.9k
  • proliferation3.9k

Top pathways disrupted

  • pi3k akt mtor signaling10.0k
  • apical junction9.8k
  • allograft rejection9.4k

Resistance landscape — Ripretinib

MeasuredReference

10 known oncogenic variants exist on Ripretinib's top targets — see detail for inhibition impact.

Open in new tab